Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott following the news California-based investment bank Roth Capital Partners has initiated coverage with a Buy rating and a 12-month price target of 13 cents. She says it's a great accomplishment for them to be told they're a buy and that's only on three of their compounds.
Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment'
Quick facts: Imugene Ltd
Price: 0.063 AUD
Market Cap: $276.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE